JPRN-UMIN000030782招募中2 期
Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated or treated PD-L1 positive advanced non-small cell lung cancer - Phase II study of pembrolizumab for advanced NSCLC patients with poor PS
Department of Respiratory Medicine and Thoracic Oncology, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital0 个研究点目标入组 32 人开始时间: 2018年1月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The age of less than 20 2) Indicative for cytotoxic chemotherapy or molecular targeted agents 3) Uncontrolled brain metastasis treated by palliative radiotherapy 4) Clinically active infection 5) Severe complication (cardiac diseases, interstitial pneumonia, uncontrolled hypertension or diabetes) 6) Uncontrolled pleural effusion 7) Active other organ cancers 8) History of severe drug allergy 9) Uncontrolled digestive ulcer 10) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
已完成
2 期
Phase II study for efficacy and safety of pembrolizumab for chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancerlung cancerJPRN-UMIN000026259Department of Respiratory Medicine and Thoracic Oncology, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital20
进行中（未招募）
2 期
Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaCarcinoma, HepatocellularNCT05389527Shanghai Zhongshan Hospital43
Unknown
2 期
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT04995016Tianjin Medical University Second Hospital18
进行中（未招募）
1 期
Phase II Clinical Trial of MK-3475 in subjects with refractory HNSCCRecurrent/metastatic head and neck squamous cell carcinomaEUCTR2014-002447-18-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc150
进行中（未招募）
1 期
A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab - Phase II Clinical Trial of MK-3475 in subjects with refractory HNSCCRecurrent/metastatic head and neck squamous cell carcinomaMedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002447-18-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc150